The primary treatment for the rare bleeding disorder hereditary factor X deficiency has now been initiated across the UK.
The UK is the first country in Europe where Coagadex will be made available, via a Commercial Medicines Unit tender, which starts on July 1st.
Bio Products Laboratory’s Coagadex was accepted in Europe in March for the treatment and prophylaxis of bleeding as well as for perioperative management in patients with this state.
According to Dr Steve Austin, director of St George’s University Hospitals NHS Foundation Trust, London “The prior focus has been on treating Factor X deficiency with blood infusions of plasma. For the first time, patients with this exceptional bleeding disorder can receive a definite factor X replacement that has been proven useful and successful in clinical studies.”
Hereditary factor X deficiency has an impact around 700 patients in Europe, and is described by a lack of factor X protein in the blood, which plays a critical role in coagulation.
People with this insufficiency are at bigger risk of bleeding, including inside the brain, lungs or gastrointestinal tract in the most severe cases, which can be life-threatening.
The CMU works on behalf of the Department of Health and the NHS and in corporation with the people who buy pharmaceuticals for hospitals across the NHS in the UK.
Date: 7th June 2016
http://www.pharmatimes.com/news/uk_launch_for_first_hereditary_factor_x_deficiency_treatment_1035301